{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:22:02Z","timestamp":1792707722406,"version":"4.5.0"},"reference-count":136,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,10,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Sickle cell disease (SCD) is an inherited monogenic red blood cell disorder affecting millions worldwide. SCD causes vascular occlusions, chronic hemolytic anemia, and cumulative organ damage such as nephropathy, pulmonary hypertension, pathologic heart remodeling, and liver necrosis. Coagulation system activation, a conspicuous feature of SCD that causes chronic inflammation, is an important component of SCD pathophysiology. The key coagulation factor, thrombin (factor IIa [FIIa]), is both a central protease in hemostasis and thrombosis and a key modifier of inflammation. Pharmacologic or genetic reduction of circulating prothrombin in Berkeley sickle mice significantly improves survival, ameliorates vascular inflammation, and results in markedly reduced end-organ damage. Accordingly, factors both upstream and downstream of thrombin, such as the tissue factor\u2013FX complex, fibrinogen, platelets, von Willebrand factor, FXII, high-molecular-weight kininogen, etc, also play important roles in SCD pathogenesis. In this review, we discuss the various aspects of coagulation system activation and their roles in the pathophysiology of SCD.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019000193","type":"journal-article","created":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T18:36:03Z","timestamp":1571769363000},"page":"3170-3180","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":62,"title":["Role of the coagulation system in the pathogenesis of sickle cell disease"],"prefix":"10.1182","volume":"3","author":[{"given":"Md","family":"Nasimuzzaman","sequence":"first","affiliation":[{"name":"Division of Experimental Hematology and Cancer Biology, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH; and"},{"name":"Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Punam","family":"Malik","sequence":"additional","affiliation":[{"name":"Division of Experimental Hematology and Cancer Biology, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH; and"},{"name":"Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,10,22]]},"reference":[{"issue":"11","key":"2019111523515126700_B1","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1056\/NEJM199709113371107","article-title":"Pathogenesis and treatment of sickle cell disease","volume":"337","author":"Bunn","year":"1997","journal-title":"N Engl J Med"},{"issue":"9757","key":"2019111523515126700_B2","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(10)61029-X","article-title":"Sickle-cell disease","volume":"376","author":"Rees","year":"2010","journal-title":"Lancet"},{"issue":"23","key":"2019111523515126700_B3","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1056\/NEJM199406093302303","article-title":"Mortality in sickle cell disease. Life expectancy and risk factors for early death","volume":"330","author":"Platt","year":"1994","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111523515126700_B4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/ajh.21408","article-title":"The cost of health care for children and adults with sickle cell disease","volume":"84","author":"Kauf","year":"2009","journal-title":"Am J Hematol"},{"issue":"1","key":"2019111523515126700_B5","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood-2009-06-227447","article-title":"Left ventricular hypertrophy and diastolic dysfunction in children with sickle cell disease are related to asleep and waking oxygen desaturation","volume":"116","author":"Johnson","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2019111523515126700_B6","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ccm.2006.04.001","article-title":"Sickle acute lung injury: role of prevention and early aggressive intervention strategies on outcome","volume":"27","author":"Melton","year":"2006","journal-title":"Clin Chest Med"},{"issue":"8","key":"2019111523515126700_B7","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1681\/ASN.2002010084","article-title":"Glomerular involvement in adults with sickle cell hemoglobinopathies: prevalence and clinical correlates of progressive renal failure","volume":"17","author":"Guasch","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"2019111523515126700_B8","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1046\/j.1365-2141.2003.04594.x","article-title":"Causes of death in sickle cell disease: an autopsy study","volume":"123","author":"Manci","year":"2003","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111523515126700_B9","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1056\/NEJMoa1715971","article-title":"A phase 3 trial of l-glutamine in sickle cell disease","volume":"379","author":"Niihara","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111523515126700_B10","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease","volume":"376","author":"Ataga","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111523515126700_B11","doi-asserted-by":"crossref","first-page":"932","DOI":"10.7326\/0003-4819-148-12-200806170-00220","article-title":"National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease","volume":"148","author":"Brawley","year":"2008","journal-title":"Ann Intern Med"},{"issue":"6","key":"2019111523515126700_B12","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJM199608083350601","article-title":"Bone marrow transplantation for sickle cell disease","volume":"335","author":"Walters","year":"1996","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111523515126700_B13","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1172\/JCI30920","article-title":"Sickle cell disease: old discoveries, new concepts, and future promise","volume":"117","author":"Frenette","year":"2007","journal-title":"J Clin Invest"},{"issue":"3","key":"2019111523515126700_B14","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1172\/JCI10726","article-title":"Sickle cell anemia as an inflammatory disease","volume":"106","author":"Platt","year":"2000","journal-title":"J Clin Invest"},{"issue":"15","key":"2019111523515126700_B15","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1182\/blood-2015-01-625707","article-title":"Genetic diminution of circulating prothrombin ameliorates multiorgan pathologies in sickle cell disease mice","volume":"126","author":"Arumugam","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2019111523515126700_B16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bjh.12336","article-title":"Interplay between coagulation and vascular inflammation in sickle cell disease","volume":"162","author":"Sparkenbaugh","year":"2013","journal-title":"Br J Haematol"},{"issue":"7","key":"2019111523515126700_B17","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1182\/blood-2015-09-618538","article-title":"Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology","volume":"127","author":"Zhang","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2019111523515126700_B18","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.blre.2015.12.003","article-title":"Coagulation abnormalities of sickle cell disease: relationship with clinical outcomes and the effect of disease modifying therapies","volume":"30","author":"Noubouossie","year":"2016","journal-title":"Blood Rev"},{"issue":"3","key":"2019111523515126700_B19","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/blood-2012-04-424143","article-title":"Tissue factor promotes activation of coagulation and inflammation in a mouse model of sickle cell disease","volume":"120","author":"Chantrathammachart","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2019111523515126700_B20","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1182\/blood.V97.6.1584","article-title":"Endothelial dysfunction in patients with sickle cell disease is related to selective impairment of shear stress-mediated vasodilation","volume":"97","author":"Belhassen","year":"2001","journal-title":"Blood"},{"issue":"2","key":"2019111523515126700_B21","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1046\/j.1365-2141.2000.02353.x","article-title":"Platelet and leucocyte activation in childhood sickle cell disease: association with nocturnal hypoxaemia","volume":"111","author":"Inwald","year":"2000","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111523515126700_B22","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1182\/blood.V88.6.2311.bloodjournal8862311","article-title":"Vascular cell adhesion molecule-1 is involved in mediating hypoxia-induced sickle red blood cell adherence to endothelium: potential role in sickle cell disease","volume":"88","author":"Setty","year":"1996","journal-title":"Blood"},{"issue":"3","key":"2019111523515126700_B23","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1182\/blood.V96.3.1119","article-title":"Fetal hemoglobin in sickle cell disease: relationship to erythrocyte phosphatidylserine exposure and coagulation activation","volume":"96","author":"Setty","year":"2000","journal-title":"Blood"},{"issue":"5","key":"2019111523515126700_B24","first-page":"1087","article-title":"Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis","volume":"134","author":"Drake","year":"1989","journal-title":"Am J Pathol"},{"issue":"5","key":"2019111523515126700_B25","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1213\/ane.0b013e31819bceb1","article-title":"The role of tissue factor and factor VIIa in hemostasis","volume":"108","author":"Mackman","year":"2009","journal-title":"Anesth Analg"},{"issue":"3","key":"2019111523515126700_B26","first-page":"170","article-title":"The tissue factor pathway of blood coagulation","volume":"29","author":"Nemerson","year":"1992","journal-title":"Semin Hematol"},{"issue":"5","key":"2019111523515126700_B27","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1055\/s-0038-1646454","article-title":"An anti-tissue factor monoclonal antibody which inhibits TF.VIIa complex is a potent anticoagulant in plasma","volume":"66","author":"Ruf","year":"1991","journal-title":"Thromb Haemost"},{"issue":"4","key":"2019111523515126700_B28","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/0092-8674(88)90567-3","article-title":"The molecular basis of blood coagulation","volume":"53","author":"Furie","year":"1988","journal-title":"Cell"},{"issue":"9","key":"2019111523515126700_B29","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1172\/JCI1932","article-title":"Tissue factor expression by endothelial cells in sickle cell anemia","volume":"101","author":"Solovey","year":"1998","journal-title":"J Clin Invest"},{"key":"2019111523515126700_B30","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.thromres.2010.01.042","article-title":"Cellular sources of tissue factor in endotoxemia and sepsis","volume":"125","author":"Pawlinski","year":"2010","journal-title":"Thromb Res"},{"issue":"3","key":"2019111523515126700_B31","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2003-10-3719","article-title":"Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia\/reoxygenation and inhibited by lovastatin","volume":"104","author":"Solovey","year":"2004","journal-title":"Blood"},{"issue":"1","key":"2019111523515126700_B32","doi-asserted-by":"crossref","first-page":"e87243","DOI":"10.1371\/journal.pone.0087243","article-title":"Plasma concentration of platelet-derived microparticles is related to painful vaso-occlusive phenotype severity in sickle cell anemia","volume":"9","author":"Nebor","year":"2014","journal-title":"PLoS One"},{"issue":"7","key":"2019111523515126700_B33","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1182\/blood-2003-03-0693","article-title":"Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes","volume":"102","author":"Shet","year":"2003","journal-title":"Blood"},{"issue":"11","key":"2019111523515126700_B34","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.3324\/haematol.2009.008938","article-title":"Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease","volume":"94","author":"van Beers","year":"2009","journal-title":"Haematologica"},{"issue":"10","key":"2019111523515126700_B35","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1182\/blood-2015-11-681114","article-title":"Thrombin-independent contribution of tissue factor to inflammation and cardiac hypertrophy in a mouse model of sickle cell disease","volume":"127","author":"Sparkenbaugh","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2019111523515126700_B36","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41573-018-0003-2","article-title":"Therapeutic strategies for sickle cell disease: towards a multi-agent approach","volume":"18","author":"Telen","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"2019111523515126700_B37","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1365-2141.2005.05753.x","article-title":"The interactions between inflammation and coagulation","volume":"131","author":"Esmon","year":"2005","journal-title":"Br J Haematol"},{"issue":"22","key":"2019111523515126700_B38","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1161\/01.CIR.0000131660.51520.9A","article-title":"Bidirectional relation between inflammation and coagulation","volume":"109","author":"Levi","year":"2004","journal-title":"Circulation"},{"issue":"6694","key":"2019111523515126700_B39","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/29325","article-title":"A dual thrombin receptor system for platelet activation","volume":"394","author":"Kahn","year":"1998","journal-title":"Nature"},{"issue":"6","key":"2019111523515126700_B40","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1172\/JCI6042","article-title":"Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin","volume":"103","author":"Kahn","year":"1999","journal-title":"J Clin Invest"},{"issue":"9","key":"2019111523515126700_B41","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1182\/blood-2003-04-1130","article-title":"Protease-activated receptors 1 and 4 mediate thrombin signaling in endothelial cells","volume":"102","author":"Kataoka","year":"2003","journal-title":"Blood"},{"issue":"8","key":"2019111523515126700_B42","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1111\/j.1538-7836.2005.01377.x","article-title":"Protease-activated receptors in hemostasis, thrombosis and vascular biology","volume":"3","author":"Coughlin","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"7","key":"2019111523515126700_B43","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.4049\/jimmunol.168.7.3577","article-title":"Activation of protease-activated receptor (PAR)-1, PAR-2, and PAR-4 stimulates IL-6, IL-8, and prostaglandin E2 release from human respiratory epithelial cells","volume":"168","author":"Asokananthan","year":"2002","journal-title":"J Immunol"},{"issue":"5","key":"2019111523515126700_B44","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1006\/cyto.2002.2001","article-title":"Thrombin enhancement of interleukin-1 expression in mononuclear cells: involvement of proteinase-activated receptor-1","volume":"20","author":"Naldini","year":"2002","journal-title":"Cytokine"},{"issue":"pt 1","key":"2019111523515126700_B45","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1042\/bj3330121","article-title":"Thrombin stimulates fibroblast procollagen production via proteolytic activation of protease-activated receptor 1","volume":"333","author":"Chambers","year":"1998","journal-title":"Biochem J"},{"issue":"6","key":"2019111523515126700_B46","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nm1419","article-title":"Generation of C5a in the absence of C3: a new complement activation pathway","volume":"12","author":"Huber-Lang","year":"2006","journal-title":"Nat Med"},{"issue":"24","key":"2019111523515126700_B47","doi-asserted-by":"crossref","first-page":"18337","DOI":"10.1074\/jbc.M001529200","article-title":"The activation state of alphavbeta 3 regulates platelet and lymphocyte adhesion to intact and thrombin-cleaved osteopontin","volume":"275","author":"Helluin","year":"2000","journal-title":"J Biol Chem"},{"issue":"5","key":"2019111523515126700_B48","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1091\/mbc.5.5.565","article-title":"Adhesive properties of osteopontin: regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain","volume":"5","author":"Senger","year":"1994","journal-title":"Mol Biol Cell"},{"issue":"3","key":"2019111523515126700_B49","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1182\/blood-2008-07-169003","article-title":"Genetic elimination of prothrombin in adult mice is not compatible with survival and results in spontaneous hemorrhagic events in both heart and brain","volume":"113","author":"Mullins","year":"2009","journal-title":"Blood"},{"issue":"7182","key":"2019111523515126700_B50","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/nature06559","article-title":"Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets","volume":"451","author":"Han","year":"2008","journal-title":"Nature"},{"issue":"23","key":"2019111523515126700_B51","doi-asserted-by":"crossref","first-page":"6326","DOI":"10.1182\/blood-2010-08-304915","article-title":"The development of inflammatory joint disease is attenuated in mice expressing the anticoagulant prothrombin mutant W215A\/E217A","volume":"117","author":"Flick","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2019111523515126700_B52","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1084\/jem.191.3.455","article-title":"Protease-activated receptor 1 mediates thrombin-dependent, cell-mediated renal inflammation in crescentic glomerulonephritis","volume":"191","author":"Cunningham","year":"2000","journal-title":"J Exp Med"},{"issue":"5","key":"2019111523515126700_B53","doi-asserted-by":"crossref","first-page":"C1264","DOI":"10.1152\/ajpcell.00177.2004","article-title":"Primary granule release from human neutrophils is potentiated by soluble fibrinogen through a mechanism depending on multiple intracellular signaling pathways","volume":"287","author":"Tuluc","year":"2004","journal-title":"Am J Physiol Cell Physiol"},{"issue":"1","key":"2019111523515126700_B54","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3324\/haematol.11763","article-title":"Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension","volume":"93","author":"Ataga","year":"2008","journal-title":"Haematologica"},{"issue":"9","key":"2019111523515126700_B55","first-page":"574","article-title":"Preliminary trial of minidose heparin prophylaxis for painful sickle cell crises","volume":"66","author":"Chaplin","year":"1989","journal-title":"East Afr Med J"},{"issue":"2","key":"2019111523515126700_B56","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1160\/Th06-12-0718","article-title":"Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial","volume":"98","author":"Qari","year":"2007","journal-title":"Thromb Haemost"},{"issue":"4","key":"2019111523515126700_B57","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1056\/NEJM196307252690403","article-title":"Long-term anti-coagulation in sickle-cell disease. A clinical study","volume":"269","author":"Salvaggio","year":"1963","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111523515126700_B58","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1056\/NEJM195702212560807","article-title":"Long-term dicumarol administration as a therapeutic trial in sicklemia; report of a case","volume":"256","author":"Adelson","year":"1957","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111523515126700_B59","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1182\/blood-2013-08-523936","article-title":"Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease","volume":"123","author":"Sparkenbaugh","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2019111523515126700_B60","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1109719","article-title":"Thrombin-receptor antagonist vorapaxar in acute coronary syndromes","volume":"366","author":"Tricoci","year":"2012","journal-title":"N Engl J Med"},{"issue":"17","key":"2019111523515126700_B61","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1161\/CIRCULATIONAHA.110.001404","article-title":"Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin\u2013Coronary Artery Disease Trial","volume":"123","author":"Wiviott","year":"2011","journal-title":"Circulation"},{"issue":"371","key":"2019111523515126700_B62","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf5294","article-title":"Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding","volume":"9","author":"Wong","year":"2017","journal-title":"Sci Transl Med"},{"issue":"2","key":"2019111523515126700_B63","first-page":"858","article-title":"Hemostatic factors and inflammatory disease","volume":"82","author":"Degen","year":"1999","journal-title":"Thromb Haemost"},{"key":"2019111523515126700_B64","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0049-3848(12)70143-3","article-title":"Hemostatic factors, innate immunity and malignancy","volume":"129","author":"Degen","year":"2012","journal-title":"Thromb Res"},{"issue":"1","key":"2019111523515126700_B65","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00281-011-0290-8","article-title":"Fibrinogen as a key regulator of inflammation in disease","volume":"34","author":"Davalos","year":"2012","journal-title":"Semin Immunopathol"},{"issue":"3","key":"2019111523515126700_B66","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.4049\/jimmunol.166.3.2002","article-title":"Fibrinogen promotes neutrophil activation and delays apoptosis","volume":"166","author":"Rubel","year":"2001","journal-title":"J Immunol"},{"issue":"11","key":"2019111523515126700_B67","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1172\/JCI30134","article-title":"Fibrin(ogen) exacerbates inflammatory joint disease through a mechanism linked to the integrin alphaMbeta2 binding motif","volume":"117","author":"Flick","year":"2007","journal-title":"J Clin Invest"},{"issue":"12","key":"2019111523515126700_B68","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1161\/ATVBAHA.110.211615","article-title":"P-selectin-mediated platelet-neutrophil aggregate formation activates neutrophils in mouse and human sickle cell disease","volume":"30","author":"Polanowska-Grabowska","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"2019111523515126700_B69","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.blre.2006.06.001","article-title":"Platelet-neutrophil-interactions: linking hemostasis and inflammation","volume":"21","author":"Zarbock","year":"2007","journal-title":"Blood Rev"},{"issue":"5","key":"2019111523515126700_B70","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0022-2143(97)90005-6","article-title":"Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia","volume":"129","author":"Wun","year":"1997","journal-title":"J Lab Clin Med"},{"key":"2019111523515126700_B71","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1749-6632.2001.tb03521.x","article-title":"Platelet-fibrinogen interactions","volume":"936","author":"Bennett","year":"2001","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"2019111523515126700_B72","first-page":"36","article-title":"Plasma fibrinogen levels in sickle cell disease","volume":"39","author":"Famodu","year":"1987","journal-title":"Trop Geogr Med"},{"issue":"1","key":"2019111523515126700_B73","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/03630260601059217","article-title":"Plasma fibrinogen levels in Nigerian homozygous (Hb SS) sickle cell patients","volume":"31","author":"Buseri","year":"2007","journal-title":"Hemoglobin"},{"issue":"12","key":"2019111523515126700_B74","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/ajh.20982","article-title":"Fibrinogen deficiency, but not plasminogen deficiency, increases mortality synergistically in combination with sickle hemoglobin SAD in transgenic mice","volume":"82","author":"Roszell","year":"2007","journal-title":"Am J Hematol"},{"issue":"11","key":"2019111523515126700_B75","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V104.11.236.236","article-title":"Tissue factor deficiency decreases sickle cell-induced vascular stasis in a hematopoietic stem cell transplant model of murine sickle cell disease","volume":"104","author":"Hillery","year":"2004","journal-title":"Blood."},{"issue":"21","key":"2019111523515126700_B76","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1056\/NEJM199905273402103","article-title":"Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators","volume":"340","author":"Hamm","year":"1999","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111523515126700_B77","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJM199808133390704","article-title":"Inhibition of platelet glycoprotein IIb\/IIIa with eptifibatide in patients with acute coronary syndromes","volume":"339","author":"Platelet Glycoprotein IIb\/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators","year":"1998","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111523515126700_B78","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.thromres.2013.08.002","article-title":"A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease","volume":"132","author":"Desai","year":"2013","journal-title":"Thromb Res"},{"issue":"3","key":"2019111523515126700_B79","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-2141.2005.05444.x","article-title":"Molecular mechanisms of fibrinolysis","volume":"129","author":"Cesarman-Maus","year":"2005","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111523515126700_B80","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00282-997-0229-7","article-title":"Fibrinolytic response to venous occlusion in patients with homozygous sickle cell disease","volume":"39","author":"Nsiri","year":"1997","journal-title":"Hematol Cell Ther"},{"issue":"2","key":"2019111523515126700_B81","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00001721-199504000-00001","article-title":"Changes in coagulation and fibrinolysis in patients with sickle cell disease compared with healthy black controls","volume":"6","author":"Hagger","year":"1995","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"3","key":"2019111523515126700_B82","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00282-996-0279-2","article-title":"Abnormalities of coagulation and fibrinolysis in homozygous sickle cell disease","volume":"38","author":"Nsiri","year":"1996","journal-title":"Hematol Cell Ther"},{"issue":"3","key":"2019111523515126700_B83","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1159\/000362148","article-title":"Hydroxyurea increases plasma concentrations of microparticles and reduces coagulation activation and fibrinolysis in patients with sickle cell anemia","volume":"133","author":"Brunetta","year":"2015","journal-title":"Acta Haematol"},{"issue":"2","key":"2019111523515126700_B84","first-page":"186","article-title":"Platelet activation and blood coagulation","volume":"88","author":"Heemskerk","year":"2002","journal-title":"Thromb Haemost"},{"issue":"6","key":"2019111523515126700_B85","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1182\/blood-2006-12-061697","article-title":"Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin","volume":"110","author":"Villagra","year":"2007","journal-title":"Blood"},{"issue":"22","key":"2019111523515126700_B86","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1182\/blood-2015-02-626234","article-title":"Hydroxyurea with AKT2 inhibition decreases vaso-occlusive events in sickle cell disease mice","volume":"126","author":"Barazia","year":"2015","journal-title":"Blood"},{"issue":"14","key":"2019111523515126700_B87","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1096\/fj.04-2317fje","article-title":"Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension","volume":"18","author":"Xu","year":"2004","journal-title":"FASEB J"},{"issue":"6","key":"2019111523515126700_B88","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1161\/01.HYP.0000018041.48432.B5","article-title":"Nitric oxide modulates superoxide release and peroxynitrite formation in human blood vessels","volume":"39","author":"Guzik","year":"2002","journal-title":"Hypertension"},{"issue":"1","key":"2019111523515126700_B89","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1021\/tx980207u","article-title":"Nitration of unsaturated fatty acids by nitric oxide-derived reactive nitrogen species peroxynitrite, nitrous acid, nitrogen dioxide, and nitronium ion","volume":"12","author":"O\u2019Donnell","year":"1999","journal-title":"Chem Res Toxicol"},{"issue":"8","key":"2019111523515126700_B90","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1161\/hh0801.089861","article-title":"Nitric oxide insufficiency, platelet activation, and arterial thrombosis","volume":"88","author":"Loscalzo","year":"2001","journal-title":"Circ Res"},{"issue":"4","key":"2019111523515126700_B91","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1046\/j.1365-2141.1998.00627.x","article-title":"Platelet activation in patients with sickle cell disease","volume":"100","author":"Wun","year":"1998","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111523515126700_B92","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000207105","article-title":"Therapeutic effect of aspirin in sickle cell anaemia","volume":"66","author":"Osamo","year":"1981","journal-title":"Acta Haematol"},{"issue":"5","key":"2019111523515126700_B93","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0022-3476(83)80258-3","article-title":"Trial of low doses of aspirin as prophylaxis in sickle cell disease","volume":"102","author":"Greenberg","year":"1983","journal-title":"J Pediatr"},{"issue":"1","key":"2019111523515126700_B94","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000206360","article-title":"Treatment of sickle cell diseases with aspirin","volume":"72","author":"Zago","year":"1984","journal-title":"Acta Haematol"},{"issue":"7","key":"2019111523515126700_B95","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1512021","article-title":"A multinational trial of prasugrel for sickle cell vaso-occlusive events","volume":"374","author":"Heeney","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111523515126700_B96","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1080\/13543784.2017.1335710","article-title":"Prasugrel hydrochloride for the treatment of sickle cell disease","volume":"26","author":"Conran","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"2019111523515126700_B97","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1756-8722-6-17","article-title":"A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease","volume":"6","author":"Wun","year":"2013","journal-title":"J Hematol Oncol"},{"issue":"2","key":"2019111523515126700_B98","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/bjh.15646","article-title":"Ticagrelor does not impact patient-reported pain in young adults with sickle cell disease: a multicentre, randomised phase IIb study","volume":"184","author":"Kanter","year":"2019","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111523515126700_B99","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1055\/s-0038-1661088","article-title":"A double-blind trial of ticlopidine in sickle cell disease","volume":"51","author":"Semple","year":"1984","journal-title":"Thromb Haemost"},{"issue":"2","key":"2019111523515126700_B100","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1046\/j.1365-3156.2000.00507.x","article-title":"An open comparative study of dispersible piroxicam versus soluble acetylsalicylic acid for the treatment of osteoarticular painful attack during sickle cell crisis","volume":"5","author":"Eke","year":"2000","journal-title":"Trop Med Int Health"},{"issue":"13","key":"2019111523515126700_B101","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1182\/blood-2014-06-528406","article-title":"von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends","volume":"125","author":"Lenting","year":"2015","journal-title":"Blood"},{"key":"2019111523515126700_B102","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1146\/annurev.cb.06.110190.001245","article-title":"Cell biology of von Willebrand factor","volume":"6","author":"Wagner","year":"1990","journal-title":"Annu Rev Cell Biol"},{"issue":"4","key":"2019111523515126700_B103","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/blood.V70.4.895.895","article-title":"von Willebrand factor and von Willebrand disease","volume":"70","author":"Ruggeri","year":"1987","journal-title":"Blood"},{"issue":"3","key":"2019111523515126700_B104","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1172\/JCI113151","article-title":"Unusually large von Willebrand factor multimers increase adhesion of sickle erythrocytes to human endothelial cells under controlled flow","volume":"80","author":"Wick","year":"1987","journal-title":"J Clin Invest"},{"issue":"7","key":"2019111523515126700_B105","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1111\/jth.13728","article-title":"Dynamics of von Willebrand factor reactivity in sickle cell disease during vaso-occlusive crisis and steady state","volume":"15","author":"Sins","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2019111523515126700_B106","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.thromres.2007.12.004","article-title":"Increased von Willebrand factor antigen and high molecular weight multimers in sickle cell disease associated with nocturnal hypoxemia","volume":"122","author":"Krishnan","year":"2008","journal-title":"Thromb Res"},{"issue":"6","key":"2019111523515126700_B107","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1160\/TH08-10-0677","article-title":"Haemoglobin blocks von Willebrand factor proteolysis by ADAMTS-13: a mechanism associated with sickle cell disease","volume":"101","author":"Zhou","year":"2009","journal-title":"Thromb Haemost"},{"key":"2019111523515126700_B108","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.thromres.2014.03.018","article-title":"Physiologic activities of the contact activation system","volume":"133","author":"Schmaier","year":"2014","journal-title":"Thromb Res"},{"issue":"3","key":"2019111523515126700_B109","doi-asserted-by":"crossref","first-page":"234","DOI":"10.2174\/187152509789105444","article-title":"Human plasma kallikrein-kinin system: physiological and biochemical parameters","volume":"7","author":"Bryant","year":"2009","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"issue":"3","key":"2019111523515126700_B110","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/ijlh.12222","article-title":"Tracking down contact activation - from coagulation in vitro to inflammation in vivo","volume":"36","author":"de Maat","year":"2014","journal-title":"Int J Lab Hematol"},{"issue":"22","key":"2019111523515126700_B111","doi-asserted-by":"crossref","first-page":"Abstract 162","DOI":"10.1182\/blood.V128.22.162.162","article-title":"FXIIa differentially regulates thrombin generation during steady state and vaso-occlusive crisis in sickle cell mice [abstract]","volume":"128","author":"Sparkenbaugh","year":"2016","journal-title":"Blood"},{"issue":"suppl 1","key":"2019111523515126700_B112","doi-asserted-by":"crossref","first-page":"Abstract 268","DOI":"10.1182\/blood-2018-99-116526","article-title":"High molecular weight kininogen contributes to end-organ damage and mortality in a mouse model of sickle cell disease [abstract]","volume":"132","author":"Sparkenbaugh","year":"2018","journal-title":"Blood"},{"issue":"5","key":"2019111523515126700_B113","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/labinvest.3780067","article-title":"Neutrophils: molecules, functions and pathophysiological aspects","volume":"80","author":"Witko-Sarsat","year":"2000","journal-title":"Lab Invest"},{"issue":"5663","key":"2019111523515126700_B114","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1126\/science.1092385","article-title":"Neutrophil extracellular traps kill bacteria","volume":"303","author":"Brinkmann","year":"2004","journal-title":"Science"},{"issue":"6","key":"2019111523515126700_B115","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nm.1959","article-title":"Netting neutrophils in autoimmune small-vessel vasculitis","volume":"15","author":"Kessenbrock","year":"2009","journal-title":"Nat Med"},{"issue":"36","key":"2019111523515126700_B116","doi-asserted-by":"crossref","first-page":"15880","DOI":"10.1073\/pnas.1005743107","article-title":"Extracellular DNA traps promote thrombosis","volume":"107","author":"Fuchs","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"2019111523515126700_B117","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1172\/JCI61303","article-title":"Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury","volume":"122","author":"Caudrillier","year":"2012","journal-title":"J Clin Invest"},{"issue":"24","key":"2019111523515126700_B118","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2013-10-529982","article-title":"Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease","volume":"123","author":"Chen","year":"2014","journal-title":"Blood"},{"key":"2019111523515126700_B119","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fimmu.2015.00262","article-title":"Complement system part I - molecular mechanisms of activation and regulation","volume":"6","author":"Merle","year":"2015","journal-title":"Front Immunol"},{"key":"2019111523515126700_B120","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3389\/fimmu.2015.00257","article-title":"Complement system part II: role in immunity","volume":"6","author":"Merle","year":"2015","journal-title":"Front Immunol"},{"issue":"3","key":"2019111523515126700_B121","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1172\/JCI116706","article-title":"Activation of the alternative complement pathway by exposure of phosphatidylethanolamine and phosphatidylserine on erythrocytes from sickle cell disease patients","volume":"92","author":"Wang","year":"1993","journal-title":"J Clin Invest"},{"issue":"3 pt 1","key":"2019111523515126700_B122","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1006\/clin.1995.1131","article-title":"Complement activation during painful crisis in sickle cell anemia","volume":"76","author":"Mold","year":"1995","journal-title":"Clin Immunol Immunopathol"},{"issue":"2","key":"2019111523515126700_B123","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1006\/clin.1994.1072","article-title":"Activation of the alternative complement pathway by red blood cells from patients with sickle cell disease","volume":"71","author":"Chudwin","year":"1994","journal-title":"Clin Immunol Immunopathol"},{"issue":"12","key":"2019111523515126700_B124","doi-asserted-by":"crossref","first-page":"96910","DOI":"10.1172\/jci.insight.96910","article-title":"Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles","volume":"3","author":"Merle","year":"2018","journal-title":"JCI Insight"},{"issue":"12","key":"2019111523515126700_B125","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.3324\/haematol.2017.174201","article-title":"In vitro evidence of complement activation in patients with sickle cell disease","volume":"102","author":"Gavriilaki","year":"2017","journal-title":"Haematologica"},{"issue":"6398","key":"2019111523515126700_B126","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/359848a0","article-title":"Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets","volume":"359","author":"Palabrica","year":"1992","journal-title":"Nature"},{"issue":"3","key":"2019111523515126700_B127","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1055\/s-0038-1649615","article-title":"The platelet glycoprotein IIb\/IIIa complex is involved in the adhesion of activated platelets to leukocytes","volume":"70","author":"Spangenberg","year":"1993","journal-title":"Thromb Haemost"},{"issue":"3-4","key":"2019111523515126700_B128","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/09537109876780","article-title":"Role of GPIIb-IIIa in platelet-monocyte and platelet-neutrophil conjugate formation in whole blood","volume":"9","author":"Sanderson","year":"1998","journal-title":"Platelets"},{"issue":"1","key":"2019111523515126700_B129","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1182\/blood.V88.1.146.146","article-title":"Neutrophil rolling, arrest, and transmigration across activated, surface-adherent platelets via sequential action of P-selectin and the beta 2-integrin CD11b\/CD18","volume":"88","author":"Diacovo","year":"1996","journal-title":"Blood"},{"issue":"11","key":"2019111523515126700_B130","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1172\/JCI20741","article-title":"Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaMbeta2\/Mac-1 is critical for host inflammatory response in vivo","volume":"113","author":"Flick","year":"2004","journal-title":"J Clin Invest"},{"issue":"9","key":"2019111523515126700_B131","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1182\/bloodadvances.2019032342","article-title":"Elimination of the fibrinogen integrin \u03b1M\u03b22-binding motif improves renal pathology in mice with sickle cell anemia","volume":"3","author":"Nasimuzzaman","year":"2019","journal-title":"Blood Adv"},{"issue":"2","key":"2019111523515126700_B132","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/10739680490278600","article-title":"Pathophysiology of stroke in sickle cell disease","volume":"11","author":"Hillery","year":"2004","journal-title":"Microcirculation"},{"issue":"3","key":"2019111523515126700_B133","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ajh.1175","article-title":"Low adjusted-dose acenocoumarol therapy in sickle cell disease: a pilot study","volume":"68","author":"Schnog","year":"2001","journal-title":"Am J Hematol"},{"issue":"3","key":"2019111523515126700_B134","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1160\/TH16-09-0731","article-title":"Real-time dose adjustment using point-of-care platelet reactivity testing in a double-blind study of prasugrel in children with sickle cell anaemia","volume":"117","author":"Jakubowski","year":"2017","journal-title":"Thromb Haemost"},{"key":"2019111523515126700_B135","first-page":"199","article-title":"Clinical and biological double-blind-study of ticlopidine in preventive treatment of sickle-cell disease crises","volume":"15","author":"Cabannes","year":"1984","journal-title":"Agents Actions Suppl"},{"issue":"4","key":"2019111523515126700_B136","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1365-2141.2007.06787.x","article-title":"Phase I study of eptifibatide in patients with sickle cell anaemia","volume":"139","author":"Lee","year":"2007","journal-title":"Br J Haematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/20\/3170\/1502749\/advancesadv2019000193.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/20\/3170\/1502749\/advancesadv2019000193.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T15:59:22Z","timestamp":1611590362000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/20\/3170\/422495\/Role-of-the-coagulation-system-in-the-pathogenesis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,22]]},"references-count":136,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2019,10,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019000193","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,22]]}}}